TY - JOUR
T1 - Second-generation cryoballoon ablation for paroxysmal atrial fibrillation
T2 - 1-year follow-up
AU - Chierchia, Gian Battista
AU - Di Giovanni, Giacomo
AU - Ciconte, Giuseppe
AU - De Asmundis, Carlo
AU - Conte, Giulio
AU - Sieira-Moret, Juan
AU - Rodriguez-Mañero, Moises
AU - Casado, Ruben
AU - Baltogiannis, Giannis
AU - Namdar, Mehdi
AU - Saitoh, Yukio
AU - Paparella, Gaetano
AU - Mugnai, Giacomo
AU - Brugada, Pedro
PY - 2014
Y1 - 2014
N2 - Background The novel cryoballoon Advance (CB-A) has proven to achieve significantly lower temperatures and faster pulmonary vein isolation (PVI) times in comparison with the first-generation device. Although acutely very effective, to the best of our knowledge, data on mid-term clinical follow-up is lacking. Aims The aim of the study was to analyse the freedom from recurrence of atrial fibrillation (AF) on a 1-year follow-up period, in a series of consecutive patients having undergone PVI with the CB-A for paroxysmal AF (PAF). Methods and results Forty-two patients [30 male (71%); mean age: 57.9 ± 21.1 years] were included. All patients underwent a procedure with the large 28 mm CB-A. A total 168 PVs were depicted on the pre-procedural computed tomography scan. All PVs (100%) could be isolated with the CB only. The freedom from AF off-antiarrhythmic drug treatment after a single procedure was 78% of patients at a mean 11.6 ± 2.0 months follow-up. If considering a blanking period (BP) of 3 months, success rate was 83%. Phrenic nerve palsy (PNP) was the most frequent complication occurring in 19% of individuals. Conclusion The CB-A is very effective in producing PVI and affords freedom from AF at 12 months follow-up in 83% of patients affected by drug-resistant PAF following a 3-month BP. The most frequent complication observed was PNP which occurred in 19% of patients. All PNP reverted during follow-up.
AB - Background The novel cryoballoon Advance (CB-A) has proven to achieve significantly lower temperatures and faster pulmonary vein isolation (PVI) times in comparison with the first-generation device. Although acutely very effective, to the best of our knowledge, data on mid-term clinical follow-up is lacking. Aims The aim of the study was to analyse the freedom from recurrence of atrial fibrillation (AF) on a 1-year follow-up period, in a series of consecutive patients having undergone PVI with the CB-A for paroxysmal AF (PAF). Methods and results Forty-two patients [30 male (71%); mean age: 57.9 ± 21.1 years] were included. All patients underwent a procedure with the large 28 mm CB-A. A total 168 PVs were depicted on the pre-procedural computed tomography scan. All PVs (100%) could be isolated with the CB only. The freedom from AF off-antiarrhythmic drug treatment after a single procedure was 78% of patients at a mean 11.6 ± 2.0 months follow-up. If considering a blanking period (BP) of 3 months, success rate was 83%. Phrenic nerve palsy (PNP) was the most frequent complication occurring in 19% of individuals. Conclusion The CB-A is very effective in producing PVI and affords freedom from AF at 12 months follow-up in 83% of patients affected by drug-resistant PAF following a 3-month BP. The most frequent complication observed was PNP which occurred in 19% of patients. All PNP reverted during follow-up.
KW - Atrial fibrillation
KW - Cryoballoon
KW - Mid-term outcomes
KW - Pulmonary vein isolation
UR - http://www.scopus.com/inward/record.url?scp=84900328447&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84900328447&partnerID=8YFLogxK
U2 - 10.1093/europace/eut417
DO - 10.1093/europace/eut417
M3 - Article
C2 - 24478116
AN - SCOPUS:84900328447
VL - 16
SP - 639
EP - 644
JO - Europace
JF - Europace
SN - 1099-5129
IS - 5
ER -